Therapeutic Effect of Green Seaweed Against Metabloc Syndrome - Trial NCT05786534
Access comprehensive clinical trial information for NCT05786534 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Veterinary and Animal Sciences, Lahore - Pakistan and is currently Enrolling by invitation. The study focuses on Metabolic Syndrome. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Veterinary and Animal Sciences, Lahore - Pakistan
Timeline & Enrollment
N/A
Dec 27, 2022
Aug 24, 2023
Primary Outcome
Blood pressure will be assessed before and after the trial,Lipid profile will be assessed before and after the trial,Fasting glucose level will be assessed before and after the trial,Weight will be measured before and after the trial
Summary
Metabolic syndrome is a major concern worldwide and in Pakistan as well. Metabolic syndrome
 is a pathologic condition which includes abdominal obesity, insulin resistance, hypertension
 and hyperlipidemia. Seafood consumption has been linked to reduced risk of many health
 conditions including altered blood profile. Green seaweed is known to have a potential in
 optimizing the blood profile and so, it is helpful in reducing the risk of metabolic syndrome
 by playing a role in preventing obesity, hyperglycemia, high blood pressure and altered lipid
 profile. Green seaweed (Ulva Lactuca) powder will prove to have therapeutic potential against
 obesity, hypertension, glucose intolerance and dyslipidemia.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05786534
Non-Device Trial